HIV therapies, typically cocktails of antiviral drugs, have proven to be very successful in controlling HIV/AIDS. However, they are not a “cure,” which is a very lofty goal. American Gene Technologies (AGT), based in Rockville, Maryland, received the go-ahead from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial of AGT103-T, a gene therapy, to eliminate HIV from infected individuals.
{iframe}https://www.biospace.com/article/fda-gives-american-gene-technologies-greenlight-to-begin-phase-i-trial-for-possible-hiv-cure/{/iframe}